4-methyl-[1,2,3]thiadiazole-5-carboxylic acid 2-methoxy-benzylamide | 69635-95-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-methyl-[1,2,3]thiadiazole-5-carboxylic acid 2-methoxy-benzylamide
• 英文别名: N-[(2-methoxyphenyl)methyl]-4-methylthiadiazole-5-carboxamide
• CAS: 69635-95-6
• 化学式: C₁₂H₁₃N₃O₂S
• 分子量: 263.32
• InChiKey: NKPFFNLPNQIICZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  92.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  邻甲氧基苄胺 、 alkaline earth salt of/the/ methylsulfuric acid 生成 4-methyl-[1,2,3]thiadiazole-5-carboxylic acid 2-methoxy-benzylamide
  参考文献：
  名称：

  [1,2,3]噻二唑坏死性凋亡抑制剂的构效关系研究。

  摘要：

  坏死性凋亡是一种受调节的半胱天冬酶非依赖性细胞死亡机制，导致类似于非调节性坏死的形态特征。这种形式的细胞死亡可以用死亡受体家族配体在凋亡缺陷条件下在一系列细胞类型中诱导。发现一系列 [1,2,3] 噻二唑苄基酰胺是有效的坏死性凋亡抑制剂（称为坏死抑制素）。构效关系研究表明，分别位于 [1,2,3] 噻二唑的 4-和 5-位的小环状烷基（即环丙基）和 2,6-二卤代苄酰胺是最佳的。此外，当苄基位置上存在小的烷基（即甲基）时，所有坏死性凋亡抑制活性都存在于（S）-对映异构体中。最后，替换 [1,2,

  DOI：

  10.1016/j.bmcl.2007.10.024

文献信息

• [EN] HETEROCYCLIC INHIBITORS OF NECROPTOSIS<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE LA NÉCROPTOSE
  申请人：HARVARD COLLEGE

  公开号：WO2009023272A1

  公开（公告）日：2009-02-19

  The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-α) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-α induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.

  该发明涉及一系列杂环衍生物，可以抑制肿瘤坏死因子α（TNF-α）诱导的坏死程序。该发明的杂环化合物由化学式（I）和（Ia）-（Ie）描述，并且已经证明可以抑制人类Jurkat T细胞中FADD缺陷变体中TNF-α诱导的坏死程序。该发明还涉及含有该发明化合物的药物组合物。该发明的化合物和组合物也可用于治疗坏死程序可能起重要作用的疾病。
• HETEROCYCLIC INHIBITORS OF NECROPTOSIS
  申请人：President and Fellows of Harvard College

  公开号：EP3034494A1

  公开（公告）日：2016-06-22

  The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-α) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-α induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.

  本发明具有一系列抑制肿瘤坏死因子α（TNF-α）诱导坏死的杂环衍生物。本发明的杂环化合物由式(I)和(Ia)-(Ie)描述，并证明可抑制FADD缺陷变体人Jurkat T细胞中TNF-α诱导的坏死。本发明还具有以本发明化合物为特征的药物组合物。本发明的化合物和组合物还可用于治疗坏死可能起重要作用的疾病。
• Heterocyclic inhibitors of necroptosis
  申请人：Cuny Gregory D.

  公开号：US20090099242A1

  公开（公告）日：2009-04-16

  The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-α) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-α induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.
• US4177054A
  申请人：——

  公开号：US4177054A

  公开（公告）日：1979-12-04
• US8278344B2
  申请人：——

  公开号：US8278344B2

  公开（公告）日：2012-10-02